These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19651760)

  • 1. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study.
    Barrios V; Escobar C; Calderón A; Echarri R; Barrios S; Navarro-Cid J
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):168-73. PubMed ID: 19651760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.
    Escobar C; Barrios V; Calderón A; Barrios S; Echarri R; Navarro-Cid J; Ferrer E; Fernandez R
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):208-14. PubMed ID: 18326961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study.
    Barrios V; Calderón A; Escobar C; Barrios S; Navarro-Cid J; González-Pedel V; Vegazo O; Fernandez R
    J Hypertens; 2007 Sep; 25(9):1967-73. PubMed ID: 17762663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study.
    Barrios V; Escobar C; Calderón A; Barrios S; Navarro-Cid J; Ferrer E; Echarri R
    Heart Vessels; 2010 Jan; 25(1):51-6. PubMed ID: 20091399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study.
    Calderón A; Barrios V; Escobar C; Ferrer E; Barrios S; González-Pedel V; Montoro P; Navarro-Cid J
    Clin Exp Hypertens; 2010 May; 32(3):145-53. PubMed ID: 20504121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
    Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
    Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
    Am Heart J; 2010 May; 159(5):833-40. PubMed ID: 20435193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
    Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
    Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study].
    González-Juanatey JR; Cea-Calvo L; Bertomeu V; Aznar J;
    Rev Esp Cardiol; 2007 Feb; 60(2):148-56. PubMed ID: 17338880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population.
    Barrios V; Escobar C; Calderon A; Ribas L; Marti D; Asin E
    Blood Press; 2008; 17(2):110-5. PubMed ID: 18568700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
    J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of left ventricular hypertrophy, atrial fibrillation and cardiovascular disease in hypertensive patients of Andalusia, Spain. PREHVIA study].
    Martín-Rioboó E; García Criado E; Pérula De Torres LA; Cea-Calvo L; Anguita Sánchez M; López Granados A; Ureña Fernández T; García Matarín L; Molina Díaz R;
    Med Clin (Barc); 2009 Feb; 132(7):243-50. PubMed ID: 19248873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.